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Abstract 
Background: Developmentally early cells are mobilized into peripheral blood in Crohn’s disease (CD) patients. OCT4, 
is considered to be important in sustaining the pluripotency of stem cells. OCT4 splicing variants are differentially 
expressed in pluripotent and non-pluripotent cells. Our study aims to investigate the expression pattern of OCT4 
variants and SOX-2, an essential factor implicated in self-renewal and pluripotency, in tissue and blood samples from 
patients with IBD.
Methods: Peripheral blood and tissue samples were collected from patients with active CD and ulcerative colitis 
(UC), and from healthy individuals. OCT4 expression was documented by Western blot, immunohistochemistry and 
by reverse transcription-real-time PCR. OCT4 isoform determination was documented using specific primers. SOX-2 
expression levels were also evaluated.
Results: OCT4 protein levels were significantly higher in CD tissue samples than in CD blood samples, and in UC 
tissue samples. OCT4 protein was localized mainly in the cytosol. In all samples, only the OCT4 pseudogenes and the 
OCT4B1 variant were detected. OCT4B1 expression levels were elevated in both tissue and blood samples from CD and 
UC cases compared to healthy controls. In CD patients only SOX-2 mRNA levels were found slightly increased com-
pared to healthy controls.
Conclusion: Our results suggest that OCT4 is expressed in patients with IBD. Furthermore, we found the presence of 
the OCT4B1 isoform in IBD in both tissue and blood samples. Our results have shown, that developmentally early cells 
might be mobilized into peripheral blood as result of tissue damage, indicating a possible role of these cells in repair 
of injured intestinal tract.
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Background
Crohn’s disease (CD) and ulcerative colitis (UC), known 
as inflammatory bowel diseases (IBDs), are chronic 
immuno-related inflammatory diseases of unknown 
aetiology. However, it has been considered that IBD 
pathogenesis is the outcome of an aggressive cell-
mediated immune reaction to commensal intestinal 
bacteria at a genetically predisposed host [1]. Mount-
ing evidence has been indicating that IBD pathogenesis 
may be influenced by the variety of cell types involved 
such as stem cells (SCs), including defects of their dif-
ferentiation [2]. SCs contribute to tissue homeostasis, 
and regeneration after damage [3]. Currently, the idea 
of SC-based therapies has been considered as a hope-
ful approach for the treatment of IBD, essentially by the 
use of hematopoietic SCs (HSCs) and mesenchymal SCs 
(MSCs) [4]. It has been supported that cells expressing 
markers for MSCs, HSCs, fibrocytes, enthothelial pro-
genitors were identified in peripheral blood (PB) during 
tissue/organ damage, inflammation, and pharmacologi-
cal therapy [5, 6]. Interestingly, Marlicz et al. [7] reported 
that cells expressing markers for MSCs, EPCs, and 
Oct-4 + Nanog + SSEA-4 + CXCR4 +  lin-CD-45-very 
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small embryonic-like stem cells (VSELs) are mobilized 
into PB in CD patients, suggesting that these cells might 
be important in the development and regeneration of 
gastrointestinal epithelium in IBD [7].
Regarding OCT4, a POU-domain transcription factor 
is considered to be a critical factor for the pluripotency 
of human embryonal stem (ES) and induced pluipo-
tency stem (IPS) cells [8]. As cells differentiate and lose 
pluripotency, OCT4 is not expressed. The human OCT4 
gene, situated on chromosome 6, consists of five exons 
and can be alternatively spliced into three basic isoforms 
OCT4A, OCT4B, and OCT4B1, and produce four pro-
teins OCT4A, OCT4B-190, OCT4B-265, and OCT4B-
164. OCT4A, usually referred as OCT4, is distinctively 
expressed in the nucleus of ESCs and regulates the 
stemness of pluripotent cells [9]. Nevertheless, the occur-
rence of transcribed pseudogenes with high homology to 
the OCT4A sequence raised questions about OCT4 as a 
pluripotency marker, and could be a possible source of 
false positive results or could lead to misinterpretation 
of RT-PCR experiments addressing in general OCT4 
expression [10, 11]. OCT4B is principally localized in 
the cytoplasm and cannot maintain the self-renewal and 
pluripotency of ESCs [12]. The role of OCT4B is still 
unclear; however, Li et  al. [13] have recently supported 
that OCT4B functioned as a non-coding RNA, modulat-
ing OCT4A expression in an miRNA-dependent manner 
[competing endogenous RNA (ceRNA) regulation] at the 
post-transcription level in tumour cell lines. The majority 
of the transcribed OCT4 pseudogenes have high homol-
ogy to the OCT4A sequence only. Even if the protein 
product of OCT4B1 is still not identified, it is known that 
OCT4B1 is mainly expressed in human ES and EC cells 
and is down regulated in accordance to their differentia-
tion [14]. Up to now, a small number of studies on OCT4 
expression distinguish the different spliced isoforms and 
limited information exists on the expression pattern of 
every isoform in different cell types.
Taken into account the complexity and variety of OCT4 
spliced variants and protein isoforms, the present study 
aimed to investigate the expression pattern of OCT4 iso-
forms in tissue and blood samples from patients with IBD.
Methods
Subjects
Fresh frozen tissue and blood samples from consecutive 
IBD patients and healthy controls were collected at the 
Colorectal and Inflammatory Bowel Diseases Unit, First 
Department of Propaedeutic Surgery of Athens Medical 
School, Athens, Greece. The diagnosis of IBD was based on 
criteria (clinical, endoscopic, radiological and pathological) 
[15]. The histological and immunohistochemical evalua-
tions were done by a “blinded” observer, a pathologist who 
was unware of the study groups. We examined colon biop-
sies and blood samples from 12 patients (7 females, 5 males, 
mean age 45.6 ± 14.5 years) with CD, and from 10 patients 
(6 females and 4 males, mean age 42.5  ±  14.5  years) 
with UC. The healthy tissue and blood cohort con-
sisted of 15 volunteers (8 females and 7 males, mean age 
51.6  ±  13  years), they underwent standard screening 
colonoscopy examination and they do not have history of 
inflammatory, autoimmune and cancer diseases. The study 
was carried out with ethics committee approval, and all 
patients and healthy individuals gave written consent.
RNA extraction and cDNA synthesis
Total RNA was extracted from the tissue and blood 
specimens using the Trizol reagent (Life Technologies, 
Grand Island, NY, USA) according to the manufacturer’s 
instructions. Reverse transcription was performed by 
incubating 1 mg of total RNA for 1 h at 42 °C in the pres-
ence of 500 mg/ml of Oligo dT 12–18, 10 mM deoxyri-
bonucleotide triphosphates, 5× first-strand buffer, 0.1 M 
dithiothreitol, and 200 U/ml MMLV reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA). Prior to RT-PCR analy-
sis, all of the RNA samples used had been DNase-treated 
to reduce the risk of DNA contamination. Quantitative 
Real-Time Reverse Transcription PCR analysis (Real-
Time RT-PCR) for OCT4 gene expression and for OCT4 
isoform identification was performed as previously 
described [10].
Western blot analysis
Frozen tissues were thawed and disrupted with a tissue 
lyser in RIPA buffer. Total proteins were quantified by the 
Lowry method. The same procedure was followed for the 
blood samples also. Equal concentration of proteins was 
loaded into an 8–12 % SDS-polyacrylamide gel and then 
electrotransferred. The membranes after blocking were 
incubated for 16–20 h at 4 °C with the equivalent primary 
antibody. The detection of the immune complexes after 
incubation with the appropriate peroxidase-conjugated 
secondary antibody was performed with the SuperSignal 
West Pico Chemiluminescent substrate (Pierce). Protein 
expression of the molecules was expressed as relative 
intensity, normalized to b-actin. The primary antibodies 
used in the current study were: rabbit anti-OCT4 (1:1000, 
Proteintech, 11263-1-AP), rabbit anti-SOX2 (1:1000, Cell 
Signalling Technology, 2748) and rabbit anti-beta actin 
(1:1000, Rockland antibodies & assays, 600-401-886), and 
the secondary antibody: anti-rabbit HRP (1:1000, Lifes-
pan Biosciences, LS-C56309).
Immunohistochemical analysis
Formalin-fixed paraffin-embedded (FFPE) tissue sec-
tions were deparaffinized in xylene (Carlo-Erba Reagents, 
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Milano, Italy) and rehydrated in graded alcohol. Endog-
enous peroxidase was deactivated by incubation with 
a solution of 3  % H2O2 (Sigma-Aldrich, St. Louis, MO, 
USA) in methanol (AppliChem GmbH, Darmstadt, Ger-
many) for 10 min. Six microwave heating cycles (700 W, 
4  min/cycle) with 0.01 Μ citrate buffer (pH 6.0) were 
used for antigen retrieval. Power Block reagent (Bio-
genex, USA) was used for 10  min to block non-specific 
protein binding. Sections were subsequently incubated 
with rabbit anti-OCT4 (1:100, Proteintech, 11263-1-AP) 
primary antibody. The sections were then incubated with 
One-Step Polymer HRP Reagent (Biogenex, USA) sec-
ondary antibody for 30 min. Sections were developed for 
1 min in DAB (Biogenex, USA), counterstained in Gill’s 
hematoxylin (Sigma-Aldrich), subsequently dehydrated, 
mounted and studied by light microscopy using a Leica 
CTR MIC microscope.
Statistical analysis
The statistical analyses were done using GraphPad v. 
3.00 (GraphPad Software, San Diego, CA, USA). Experi-
ments were performed in triplicates. Positivity rates and 
differences in expression among the groups were calcu-
lated using the Chi square test and the non-parametric 
Wilcoxon rank sum test, respectively. Probability values 
of <0.05 were considered significant.
Results
We first analysed the expression of OCT4 protein levels 
in blood and tissue samples from CD and UC patients. 
As indicated in Fig. 1, OCT4 was expressed in both tissue 
and blood samples from CD and UC cases. OCT4 pro-
tein levels were significantly higher in CD tissue samples 
compared to CD blood samples (p < 0.05) and to UC tis-
sue samples (p < 0.01). We also examined the expression 
of the ESC marker SOX-2 with the aim of determine if the 
OCT4 expression pattern related to a stem cell pheno-
type also. Similarly SOX-2 was significantly higher in CD 
tissue samples compared to CD blood samples (p < 0.05) 
and to UC tissue samples (p < 0.05). Interestingly, as indi-
cated in Fig.  2 OCT4 protein was expressed mainly in 
the cytosol in both CD and UC cases, which is different 
from the description about OCT4 as a nuclear protein. It 
is known that the different OCT4 isoforms can be distin-
guished by their different subcellular localization.
In order to reliably discriminate isoforms OCT4A 
from OCT4B, OCT4B1 and all the known pseudogenes 
we used the RT-PCR method followed by restriction 
Fig. 1 Representative figure of Western blot analysis of OCT4 (a), SOX2 (b) and b-actin (c) proteins, and relative expression of OCT4 and SOX2. 
Samples 1 CD tissue, 2 CD blood, 3 UC tissue, 4 UC blood. *p < 0.05; **p < 0.01
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fragment analysis and OCT4B1 specific primers as 
previously described [10, 14, 16]. As indicated in 
Fig.  3 in all cases only the OCT4 pseudogenes and the 
OCT4B1 variant were detected. The expression pattern 
of OCT4B1 variant in CD, UC and healthy tissues and 
blood samples was further examined. As indicated in 
Fig. 4, OCT4B1 expression levels were elevated in both 
tissue and blood samples from CD and UC cases com-
pared to healthy controls. Particularly, in blood sam-
ples OCT4B1 was expressed 6.95  ±  1.59-fold greater 
in CD and 3.55  ±  0.57-fold greater in UC compared 
with healthy controls. Similar results were obtained 
in tissues samples, also (5.45  ±  1.12-fold greater in 
CD and 2.74  ±  0.53-fold greater in UC, respectively). 
The OCT4B1 mRNA levels were higher in blood sam-
ples compared to tissue samples from CD patients. The 
samples from CD patients expressed higher levels of 
OCT4B1 mRNA compared to respective samples from 
the UC patients. The mRNA levels of SOX-2 were found 
slightly increased compared to healthy controls, in both 
Fig. 2 Representative immunohistochemical OCT4 expression analysis of CD and UC tissues
Fig. 3 Schematic representation of representative quantitative real-time reverse transcription PCR analysis for OCT4 isoform identification. The 
primers and the methodology used was performed as previously described [10, 14, 16]. Samples 1, 2, 3 were from tissues of healthy, CD and UC, 
respectively. Samples 4, 5, and 6 were from blood of healthy, CD and UC, respectively
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blood (0.91 ± 0.17-fold) and tissue samples (0.84 ± 0.14-
fold) of CD patients only.
Discussion
In our study, Western blot analysis of CD and UC tis-
sues and blood samples showed the expression of OCT4 
and SOX-2. Thus, in agreement with recent data from 
Marlicz et  al., our findings indicate that stem-like cells 
might exist in the tissue and blood samples from CD 
and UC patients [7]. Even if, the expression of OCT4 
has been reported mostly in human cancers and cancer 
cell lines, its expression in IBD has not been systemati-
cally investigated. In the present study, IHC analysis of 
CD and UC tissues showed that positive OCT4 stain-
ing was mainly found in the cytoplasm, which is differ-
ent from the description that OCT4 is a nuclear protein. 
Since it is known that OCT4 isoforms can be distin-
guished by their specific subcellular localization [17], in 
order to characterize OCT4 isoform and all its presently 
known pseudogenes, we used RT-PCR/restriction diges-
tion analysis, as previously described [10, 16]. Our find-
ings suggest that OCT4A and OCT4B isoforms are not 
expressed in our IBD cases however the presence of the 
OCT4 pseudogenes was found instead. It has been sug-
gested that the transcription of pseudogenes could reg-
ulate OCT4 gene activity [18]. It is interesting to notice 
that the novel OCT4 variant nominated as OCT4B1 was 
universally expressed in IBD. Atlasi et al. [14] suggested 
that while ESCs/ECs are expressed at very low levels the 
novel OCT4B isoform, i.e. the OCT4B1 variant is greatly 
expressed in these cells [7]. Consequently, our findings 
support a possible association between OCT4B1 expres-
sion and the presence of a pluripotent/undifferentiated 
state of stem cell-like cells in IBD cases, and support 
that the expression of OCT4 observed in the IBD cases is 
due to the expression of the OCT4B1 isoform. OCT4B1 
endows an anti-apoptotic property, especially under 
stress conditions [19–21]. The inhibition of apoptosis in 
an important regulatory pathway implicated in the gut 
immune system and IBD pathogenesis [22]. However, 
the mechanism by which OCT4B1 regulates the apop-
totic pathway is not yet clarified. The mRNA levels of the 
OCT4B1 were found to be higher in blood samples com-
pared to tissue samples of both CD and UC cases.
It is known that stem cells are mainly derived from bone 
marrow, and are circulating continuously at a low level in 
peripheral blood. Hematopoietic and non-hematopoi-
etic stem cells can be mobilized into peripheral blood. 
These cells are mobilized and circulate during tissue/
organ injuries. It has been suggested that mobilized cells 
have a potential role in brain regeneration after stroke, 
skin burn injury, and acute myocardial infarction [23]. 
Mobilized stem cells have multiple functions. They con-
tribute to tissue regeneration and to inflammation con-
trol by secreting several cytokines that suppress the local 
immune response [24–26]. In intestine, tissue regenera-
tion may be contributed by stem cells residing in intesti-
nal crypts. Moreover, the immune response suppressing 
role of these cells makes them a potential therapeutic tar-
get for inflammatory diseases such as IBD which is a dis-
ease with abnormal mucosal immune response. However, 
various causes may influence the number of circulating 
stem cells, such as local inflammation, strenuous exer-
cise, tissue damage and pharmacological factors [6]. It 
is lately reported that immunosuppressants such as aza-
thioprine, affect stem cell migratory behaviour and influ-
ence their therapeutic ability [27].
Conclusion
In conclusion, our findings show that the presence of 
stem cells in peripheral blood is expected. Furthermore, 
we found the presence of the OCT4B1 isoform in IBD in 
both tissue and blood samples. Our results have shown 
that patients with tissue/organ injury and inflammation 
are likely to modulate a big number of stem cells form 
bone marrow, which probably either move in the intes-
tine and contribute to regeneration or remain in circula-
tion and regulate immune response.
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